# Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

> **NCT00498979** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa-2b
- **DRUG:** cisplatin
- **DRUG:** sodium stibogluconate
- **DRUG:** dacarbazine
- **DRUG:** vinblastine

## Key facts

- **NCT ID:** NCT00498979
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-05
- **Final completion:** 2012-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498979, "Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00498979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*